115 related articles for article (PubMed ID: 36988752)
1. The Combination of Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio Predicts Survival for Non-small Cell Lung Cancer Patients.
Gong S; Yao X
Ann Surg Oncol; 2023 Jul; 30(7):4062-4063. PubMed ID: 36988752
[No Abstract] [Full Text] [Related]
2. The combination of fibrinogen concentrations and the platelet-to-lymphocyte ratio predicts survival in patients with advanced lung adenocarcinoma treated with EGFR-TKIs.
He Q; Li Y; Zhou X; Zhou W; Xia C; Zhang R; Zhang Z; Hu A; Peng S; Li J
J Int Med Res; 2021 Apr; 49(4):3000605211004021. PubMed ID: 33794676
[TBL] [Abstract][Full Text] [Related]
3. ASO Author Reflections: Clinical Significance of Combined Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio in Non-small Cell Lung Cancer.
Iwasaki M; Ishihara S; Inoue M
Ann Surg Oncol; 2022 Sep; 29(9):5708-5709. PubMed ID: 35614370
[No Abstract] [Full Text] [Related]
4. Prognostic analysis of the plasma fibrinogen combined with neutrophil-to-lymphocyte ratio in patients with non-small cell lung cancer after radical resection.
Wang GX; Huang ZN; Ye YQ; Tao SM; Xu MQ; Zhang M; Xie MR
Thorac Cancer; 2023 May; 14(15):1383-1391. PubMed ID: 37037492
[TBL] [Abstract][Full Text] [Related]
5. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer.
Wang H; Zhao J; Zhang M; Han L; Wang M; Xingde L
J Cell Physiol; 2018 May; 233(5):4216-4224. PubMed ID: 29057536
[TBL] [Abstract][Full Text] [Related]
6. Positive correlation between sarcopenia and elevation of neutrophil/lymphocyte ratio in pathological stage IIIA (N2-positive) non-small cell lung cancer patients.
Tsukioka T; Izumi N; Mizuguchi S; Kyukwang C; Komatsu H; Toda M; Hara K; Miyamoto H; Nishiyama N
Gen Thorac Cardiovasc Surg; 2018 Dec; 66(12):716-722. PubMed ID: 30105630
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of Using Combined Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio in Resectable Non-small Cell Lung Cancer.
Iwasaki M; Ishihara S; Okada S; Shimegi R; Shimomura M; Inoue M
Ann Surg Oncol; 2022 Sep; 29(9):5699-5707. PubMed ID: 35653068
[TBL] [Abstract][Full Text] [Related]
8. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in patients with non-small cell lung cancer after surgery.
Ju X; Zheng L; Niu Y; Guan H; Luo H
Asian J Surg; 2020 Sep; 43(9):940-941. PubMed ID: 32522378
[No Abstract] [Full Text] [Related]
9. Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: A meta-analysis.
Yin Y; Wang J; Wang X; Gu L; Pei H; Kuai S; Zhang Y; Shang Z
Clinics (Sao Paulo); 2015 Jul; 70(7):524-30. PubMed ID: 26222823
[TBL] [Abstract][Full Text] [Related]
10. Hyperfibrinogen Is Associated With the Systemic Inflammatory Response and Predicts Poor Prognosis in Advanced Pancreatic Cancer.
Qi Q; Geng Y; Sun M; Chen H; Wang P; Chen Z
Pancreas; 2015 Aug; 44(6):977-82. PubMed ID: 25931258
[TBL] [Abstract][Full Text] [Related]
11. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
12. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer.
Yan X; Li G
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32175568
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy.
Zattarin E; Manglaviti S; Apollonio G; Beninato T; Mazzeo L; Massa G; Bottiglieri A; Galli E; De Toma A; Occhipinti M; Brambilla M; Ferrara R; Ganzinelli M; Proto C; Garassino MC; de Braud F; Lo Russo G; Prelaj A
Future Oncol; 2022 Jul; 18(23):2593-2604. PubMed ID: 35722877
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating neutrophils and peripheral neutrophil-to-lymphocyte ratio conversely predicted the prognosis of patients with non-small cell lung cancer.
Yang R; Wang X; Ma C; Zhang Z; Liu N; Ma X; Zhang Y; Wang X; Liu Y
Cell Immunol; 2022 Sep; 379():104588. PubMed ID: 35961201
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-lymphocyte ratio predicts recurrence in patients with resected stage 1 non-small cell lung cancer.
Mizuguchi S; Izumi N; Tsukioka T; Komatsu H; Nishiyama N
J Cardiothorac Surg; 2018 Jun; 13(1):78. PubMed ID: 29945635
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer.
Sarraf KM; Belcher E; Raevsky E; Nicholson AG; Goldstraw P; Lim E
J Thorac Cardiovasc Surg; 2009 Feb; 137(2):425-8. PubMed ID: 19185164
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.
Cannon NA; Meyer J; Iyengar P; Ahn C; Westover KD; Choy H; Timmerman R
J Thorac Oncol; 2015 Feb; 10(2):280-5. PubMed ID: 25299234
[TBL] [Abstract][Full Text] [Related]
19. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
Aguiar-Bujanda D; Dueñas-Comino A; Saura-Grau S; Ros-Sanjuan L; Blanco-Sanchez MJ; Hernandez-Sosa M; Mori-De Santiago M; Galvan-Ruiz S; Lorenzo-Barreto JE; Vargas-Prado AM; Bohn-Sarmiento U
Oncol Res Treat; 2018; 41(12):755-761. PubMed ID: 30419558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
